Welcome to our dedicated page for ENDO INTL PLC ORD news (Ticker: ENDPQ), a resource for investors and traders seeking the latest updates and insights on ENDO INTL PLC ORD stock.
Endo International PLC is a global specialty pharmaceutical company committed to enhancing patients' lives and creating value through the development, manufacture, and distribution of quality branded and generic pharmaceutical products. Established in 1997, Endo operates through subsidiaries including Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, Somar, and Litha. Their business segments include U.S. branded pharmaceuticals, U.S. generic pharmaceuticals, and international pharmaceuticals, with a focus on maximizing stakeholder value through efficient operations and strategic growth opportunities. Endo recently reported financial results for the fourth quarter of 2023, highlighting revenues, losses, and segment performance.
Rhea-AI Summary
Endo International plc (ENDPQ) launches PD Pool Hall, an unscripted video series featuring real Peyronie's disease patients discussing their experiences, aiming to raise awareness and education about the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
-
Rhea-AI Summary
Endo International plc (OTC: ENDPQ) announced new presentations related to Peyronie's disease and XIAFLEX® at the Sexual Medicine Society of North America annual meeting. The presentations aim to advance medical knowledge of PD and support patient outcomes, focusing on pain, ventral curvatures, and non-responders. The company provided grants for the research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.18%
Tags
-
Rhea-AI Summary
Endo International plc reported financial results for the third quarter of 2023. Total revenues decreased by 17% compared to the same period last year. Reported loss from continuing operations was $28 million, a significant improvement from the $718 million loss in the third quarter of 2022. Adjusted income from continuing operations increased to $131 million, up from $112 million in the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
Rhea-AI Summary
Endo International's operating company, Par Pharmaceutical, has started shipping colchicine 0.6 mg capsules, the first generic version of Hikma's MITIGARE®, approved by the FDA. Colchicine capsules are used for prophylaxis of gout flares in adults. According to IQVIA™, colchicine capsules sales were approximately $65.4 million for the 12 months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
-
Rhea-AI Summary
Endo International to present data on collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis at AOFAS meeting. Results show improvement in nodule hardness and patient satisfaction. Safety profile consistent with previous studies. Treatment patterns for plantar fibromatosis also addressed. CCH not yet approved for use. Phase 3 program to begin later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
FAQ
What is the current stock price of ENDO INTL PLC ORD (ENDPQ)?
The current stock price of ENDO INTL PLC ORD (ENDPQ) is $0.0006 as of May 1, 2024.
What is the market cap of ENDO INTL PLC ORD (ENDPQ)?
The market cap of ENDO INTL PLC ORD (ENDPQ) is approximately 141.1K.
When was Endo International PLC founded?
Endo International PLC was established in 1997 through the acquisition of certain pharmaceutical products, rights, and assets from Dupont Merck Pharmaceutical Company.
What are the business segments of Endo International PLC?
Endo operates through U.S. branded pharmaceuticals, U.S. generic pharmaceuticals, and international pharmaceuticals segments.
What subsidiaries are part of Endo International PLC?
Endo's operating companies include Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, Somar, and Litha.
How does Endo International PLC maximize stakeholder value?
Endo focuses on employing an efficient operating model with disciplined execution to pursue organic growth opportunities and selective acquisitions.
What was Endo's total revenue in the fourth quarter of 2023?
Endo reported total revenues of $498 million in the fourth quarter of 2023, reflecting a 10% decrease from the previous year.
Which segments of Endo International PLC showed revenue decreases in the fourth quarter of 2023?
The Generic Pharmaceuticals and Sterile Injectables segments experienced revenue decreases, offset by increased revenues in the Branded Pharmaceuticals segment.
What is the strategic focus of Endo International PLC?
Endo aims to deliver quality, life-enhancing therapies by collaborating globally to develop treatments that benefit patients in need.
What is the recent financial achievement of Endo International PLC?
Endo successfully completed its Chapter 11 financial restructuring, reducing outstanding indebtedness and resolving prior litigation overhang.
How can stakeholders stay informed about Endo's latest updates?
Stakeholders can visit the Endo website or connect on LinkedIn to access additional resources and information on the company's operations.
What recent product launch did Par Pharmaceutical, Inc., a subsidiary of Endo International PLC, announce?
Par Pharmaceutical, Inc., launched a generic version of Amgen's DUEXIS®, reinforcing Endo's commitment to offering affordable healthcare choices.
ENDO INTL PLC ORD
OTC:ENDPQ
ENDPQ Rankings
ENDPQ Stock Data
141.13k
233.69M
0.65%
0.21%
8.47%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Dublin